Literature DB >> 14644712

Cost-utility analysis of cataract surgery in the second eye.

Brandon G Busbee1, Melissa M Brown, Gary C Brown, Sanjay Sharma.   

Abstract

OBJECTIVE: To perform a reference case cost-utility analysis of second-eye cataract surgery by using the current literature on cataract outcomes and complications.
DESIGN: Computer-based econometric modeling.
METHODS: Visual acuity data of patients treated and observed over a 4-month postoperative period were obtained from the U.S. National Cataract Patient Outcomes Research Team report. The results from this prospective study were combined with those of other studies that investigated the complication rates of cataract surgery to complete the cohort of patients and outcomes. These synthesized data were incorporated with time trade-off utility values, which accounted for prior successful cataract surgery in the fellow eye. Cost-utility determinations were made with decision analysis, and present value modeling was used to account for the time value of money and health state consequences. MAIN OUTCOME MEASURES: The number of quality-adjusted life-years (QALYs) gained was calculated for the study group undergoing second-eye cataract surgery, assuming that the postoperative vision in the second eye was equivalent to the vision in the first eye after surgery (20/27). This was divided into the cost of the procedure to find the number of year 2001 nominal U.S. dollars spent per QALY gained.
RESULTS: Second-eye cataract surgery, as compared with unilateral pseudophakia, resulted in a mean gain of 1.31 undiscounted QALYs per patient treated. A 3% annual discount rate, dependent on the duration of benefit, was used, yielding 0.92 discounted QALYs gained over a 12-year life expectancy. The mean discounted cost of treatment for each patient totaled 2509 US dollars. The cost divided by the QALYs gained (benefit) resulted in 2727 US dollars per QALY gained for this procedure. Sensitivity analysis varying costs and utility values revealed a range from 2045 US dollars to 3649 US dollars per QALY gained.
CONCLUSIONS: Second-eye cataract surgery is an extremely cost-effective procedure when compared with other interventions across medical specialties. The cost-effectiveness of second-eye surgery diminishes only slightly from the 2023 US dollars per QALY gained from first-eye cataract surgery. This suggests that patients with good vision in one eye and visual loss from cataract in the fellow eye derive substantial benefit from cataract extraction.

Entities:  

Mesh:

Year:  2003        PMID: 14644712     DOI: 10.1016/S0161-6420(03)00796-6

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  28 in total

1.  Effect of patient's life expectancy on the cost-effectiveness of treatment for ocular hypertension.

Authors:  Steven M Kymes; Michael R Plotzke; Michael A Kass; Michael V Boland; Mae O Gordon
Journal:  Arch Ophthalmol       Date:  2010-05

2.  The cost-effectiveness of second-eye cataract surgery in the UK.

Authors:  Keith Cooper; Jonathan Shepherd; Geoff Frampton; Petra Harris; Andrew Lotery
Journal:  Age Ageing       Date:  2015-09-26       Impact factor: 10.668

3.  The Royal College of Ophthalmologists' Cataract Surgery Commissioning Guidance: executive summary.

Authors:  A C Day; R Wormald; S Coronini-Cronberg; R Smith
Journal:  Eye (Lond)       Date:  2016-01-22       Impact factor: 3.775

4.  Effects of Radiation Exposure on the Cost-Effectiveness of CT Angiography and Perfusion Imaging in Aneurysmal Subarachnoid Hemorrhage.

Authors:  J Ivanidze; R A Charalel; I Shuryak; D Brenner; A Pandya; O N Kallas; K Kesavabhotla; A Z Segal; M S Simon; P C Sanelli
Journal:  AJNR Am J Neuroradiol       Date:  2017-01-12       Impact factor: 3.825

5.  Cost effectiveness of the type II Boston keratoprosthesis.

Authors:  J D Ament; T P Stryjewski; S Pujari; S Siddique; G N Papaliodis; J Chodosh; C H Dohlman
Journal:  Eye (Lond)       Date:  2010-12-24       Impact factor: 3.775

Review 6.  Value-based medicine and ophthalmology: an appraisal of cost-utility analyses.

Authors:  Gary C Brown; Melissa M Brown; Sanjay Sharma; Heidi Brown; Lindsay Smithen; David B Leeser; George Beauchamp
Journal:  Trans Am Ophthalmol Soc       Date:  2004

Review 7.  [Value-based medicine in ophthalmology].

Authors:  C Hirneiss; A S Neubauer; C Tribus; A Kampik
Journal:  Ophthalmologe       Date:  2006-06       Impact factor: 1.059

8.  The goal of value-based medicine analyses: comparability. The case for neovascular macular degeneration.

Authors:  Gary C Brown; Melissa M Brown; Heidi C Brown; Sylvia Kindermann; Sanjay Sharma
Journal:  Trans Am Ophthalmol Soc       Date:  2007

Review 9.  The surgical management of cataract: barriers, best practices and outcomes.

Authors:  Margaret A Chang; Nathan G Congdon; Shawn K Baker; Martin W Bloem; Howard Savage; Alfred Sommer
Journal:  Int Ophthalmol       Date:  2007-08-22       Impact factor: 2.031

10.  Cost-utility analysis of cataract surgery in Japan: a probabilistic Markov modeling study.

Authors:  Yoshimune Hiratsuka; Masakazu Yamada; Yoko Akune; Akira Murakami; Annabelle A Okada; Hidetoshi Yamashita; Yuichi Ohashi; Naoya Yamagishi; Hiroshi Tamura; Shunichi Fukuhara; Tomoyuki Takura
Journal:  Jpn J Ophthalmol       Date:  2013-04-16       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.